Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

Overview

To evaluate the safety and immunogenicity of COVID-19 mRNA vaccine in people aged 18 years and older, we plan to enroll 300 adult participants aged 18 years and older, divided into two groups: low- and high-dose groups. Each dose group (150 people) will be divided into 2 age groups (75 each):18 to 59 years old and ≥ 60 years old. The subjects will be randomized into vaccine group or placebo group in a ratio of 2:1. Subjects will complete 2 doses of vaccination on Day 0 and Day 21, in which the low-dose group will received 0.3 ml of the study vaccine or placebo, and the high dose group received 0.5 ml of the study vaccine or placebo.

Full Title of Study: “A Randomized, Double-blind, Dose-exploring, Placebo-controlled, Multi-center Phase II Clinical Trial Evaluating the Safety and Immunogenicity of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: May 21, 2023

Interventions

  • Biological: COVID-19 mRNA vaccine
    • 2 doses of vaccine on Day 0 and Day 21
  • Biological: Placebo
    • 2 doses of placebo on Day 0 and Day 21

Arms, Groups and Cohorts

  • Experimental: Vaccine Group, low dose, 18-59 year-old
    • 2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21
  • Experimental: Vaccine Group, low dose, 60 year-old and above
    • 2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21
  • Experimental: Vaccine Group, high dose, 18-59 year-old
    • 2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21
  • Experimental: Vaccine Group, high dose, 60 year-old and above
    • 2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21
  • Placebo Comparator: Placebo Group, low dose, 18-59 year-old
    • 2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21
  • Placebo Comparator: Placebo Group, low dose, 60 year-old and above
    • 2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21
  • Placebo Comparator: Placebo Group, high dose, 18-59 year-old
    • 2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21
  • Placebo Comparator: Placebo Group, high dose, 60 year-old and above
    • 2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21

Clinical Trial Outcome Measures

Primary Measures

  • Immunogenicity of wild type neutralizing antibodies
    • Time Frame: 28 days after complete immunization
    • GMT of wild type neutralizing antibodies
  • Immunogenicity of wild type neutralizing antibodies
    • Time Frame: 28 days after complete immunization
    • Sero-conversation rate of wild type neutralizing antibodies
  • The incidence of adverse reactions (AR)
    • Time Frame: Within 14 days of each vaccination
    • To evaluate the incidence of adverse reactions (AR) in all subjects

Secondary Measures

  • The incidence of adverse reactions (AR)
    • Time Frame: Within 28 days of complete immunization
    • To evaluate the incidence of adverse reactions (AR) in all subjects
  • The incidence of adverse reactions (AR)
    • Time Frame: Within 60 minutes of each vaccination
    • To evaluate the incidence of adverse reactions (AR) in all subjects
  • The incidence of SAE, MAE and AESI
    • Time Frame: 12 months after complete vaccination
    • To evaluation the incidence of SAE, MAE, and AESI in all subjects
  • Immunogenicity of wild type neutralizing antibodies
    • Time Frame: Before the 1st dose, 14 days after the 2nd dose, and 3, 6, 12 months after the 2nd dose
    • Sero-conversation rate of wild type neutralizing antibodies
  • Immunogenicity of wild type neutralizing antibodies
    • Time Frame: Before the 1st dose, 14 days after the 2nd dose, and 3, 6, 12 months after the 2nd dose
    • GMT of wild type neutralizing antibodies
  • Immunogenicity of wild type neutralizing antibodies
    • Time Frame: Before the 1st dose, 14 days after the 2nd dose, and 3, 6, 12 months after the 2nd dose
    • GMI of wild type neutralizing antibodies
  • Immunogenicity of wild type neutralizing antibodies
    • Time Frame: 28 days after complete immunization
    • GMI of wild type neutralizing antibodies
  • Immunogenicity of anti-S-RBD Ig G antibodies
    • Time Frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
    • Sero-conversation rate of anti-S-RBD Ig G antibodies
  • Immunogenicity of anti-S-RBD Ig G antibodies
    • Time Frame: before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
    • GMC of anti-S-RBD Ig G antibodies
  • Immunogenicity of anti-S-RBD Ig G antibodies
    • Time Frame: before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
    • GMI of anti-S-RBD Ig G antibodies
  • Cellular immunity
    • Time Frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
    • The response levels and positive rates of IL-2 produced by S protein RBD by ICS in the first 15 subjects in each group
  • Cellular immunity
    • Time Frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
    • The response levels and positive rates of IL-4 produced by S protein RBD by ICS in the first 15 subjects in each group
  • Cellular immunity
    • Time Frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
    • The response levels and positive rates of IL-5 produced by S protein RBD by ICS in the first 15 subjects in each group
  • Cellular immunity
    • Time Frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
    • The response levels and positive rates of IL-17 produced by S protein RBD by ICS in the first 15 subjects in each group
  • Cellular immunity
    • Time Frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
    • The response levels and positive rates of IFN-γ produced by S protein RBD by ICS in the first 15 subjects in each group
  • Changes in laboratory indicators
    • Time Frame: Before 1st dose and 28 days after second dose
    • Changes in white blood cell count
  • Changes in laboratory indicators
    • Time Frame: Before 1st dose and 28 days after second dose
    • Changes in neutrophils
  • Changes in laboratory indicators
    • Time Frame: Before 1st dose and 28 days after second dose
    • Changes in lymphocyte count
  • Changes in laboratory indicators
    • Time Frame: Before 1st dose and 28 days after second dose
    • Changes in platelet count
  • VOC/VOI serum cross neutralization
    • Time Frame: 28 days after complete immunization
    • To evaluated the level of VOC/VOI serum cross neutralization results in all subjects.

Participating in This Clinical Trial

Inclusion Criteria

1. Adults aged 18 years and above with BMI not lower than 18 ; 2. Volunteers are able and willing to comply with the requirements of the clinical trial protocol, and volunteers or witnesses can sign informed consent forms; 3. Willing to discuss the medical history with the investigator or doctor and allow access to all medical records related to this trial; 4. Provide 48-hour PCR negative report; 5. Have not received any other COVID-19 vaccines. Exclusion Criteria:

  • Criteria for exclusion of the first dose 1. Other medical or psychiatric conditions, including recent (within the past year) or current presence of suicidal ideation/behavior, or laboratory abnormalities that may increase the risk of participating in the study, or subjects who are not suitable to participate in the study according to the investigator's judgment; 2. Positive for human immunodeficiency virus (HIV); 3. History of infection or disease history of Middle East Respiratory Syndrome (MERS), SARS or other coronaviruses or related immunizations; 4. History of serious adverse reactions associated with the vaccine and/or a history of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine under study; 5. Immunocompromised patients with known or suspected immunodeficiency identified by medical history and/or physical examination; 6. Bleeding constitution or condition associated with prolonged bleeding which investigators believe that intramuscular injection is contraindicated; 7. Women who test positive for blood pregnancy or are breastfeeding, volunteers or their partners have a pregnancy plan within 12 months; 8. Severe hypertension and uncontrollable medication (on-site measurement: systolic blood pressure ≥ 160mmHg, diastolic blood pressure ≥ 100mmHg); 9. Have a serious chronic disease or the condition is in the progression period can not be smoothly controlled, such as diabetes, thyroid disease, etc.; 10. History of severe myocarditis, pericarditis and other heart diseases; 11. Plans to receive other vaccines within 28 days before and after receiving the test vaccine; 12. Those receiving immunosuppressive therapy, including cytotoxic drugs or systemic corticosteroids, such as for cancer or autoimmune diseases, or who were scheduled to receive treatment throughout the study period. If systemic corticosteroids are used in a short period of time (< 14 days) for the treatment of acute illness, subjects should not enter this study until at least 28 days after corticosteroid therapy has been discontinued prior to study vaccination. Inhalation/spraying, intra-articular, intraskeletal, or topical (skin or eyes) use of corticosteroids is permitted; 13. Receiving blood/plasma products or immunoglobulins 60 days prior to study vaccination or plan to receive for the entire study duration; 14. Engage in other interventional studies within 28 days prior to entering the study and/or during the study's participation; 15. Participated in other interventional studies of lipid-containing nanoparticles; 16. Have symptoms of COVID-19 such as respiratory symptoms, fever, cough, shortness of breath, and dyspnea; 17. Fever, axillary temperature > 37.0 °C. Second dose exclusion criteria:

1. Severe allergic reactions occur after the first vaccination; 2. Serious adverse reactions with causal relationship during the first vaccination; 3. Those who are newly discovered or newly occurring after the first vaccination do not meet the inclusion criteria of the first dose or meet the exclusion criteria of the first dose, and the investigator shall decide whether to continue to participate in the study; 4. Other reasons for exclusion that the investigators believe.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • CanSino Biologics Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ruihua Dong, Principal Investigator, Beijing Friendship Hospital
    • Kexin Zhao, Principal Investigator, Hebei Petro China Center Hospital
    • Tao Huang, Principal Investigator, Hunan Provincial Center for Disease Control and Prevention
  • Overall Contact(s)
    • YING WANG, 022-58213600-6051, ying.wang@cansinotech.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.